Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $42.3 million.

  • Regenxbio's Cash from Investing Activities fell 1586.02% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.1 million, marking a year-over-year decrease of 11351.87%. This contributed to the annual value of $103.4 million for FY2024, which is 4582.36% down from last year.
  • As of Q3 2025, Regenxbio's Cash from Investing Activities stood at $42.3 million, which was down 1586.02% from -$140.4 million recorded in Q2 2025.
  • Regenxbio's 5-year Cash from Investing Activities high stood at $63.1 million for Q1 2023, and its period low was -$216.4 million during Q4 2021.
  • In the last 5 years, Regenxbio's Cash from Investing Activities had a median value of $26.7 million in 2022 and averaged -$9.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 520804.81% in 2023, then crashed by 5230149.25% in 2025.
  • Regenxbio's Cash from Investing Activities (Quarter) stood at -$216.4 million in 2021, then skyrocketed by 112.34% to $26.7 million in 2022, then grew by 27.24% to $34.0 million in 2023, then grew by 18.54% to $40.3 million in 2024, then increased by 5.0% to $42.3 million in 2025.
  • Its Cash from Investing Activities stands at $42.3 million for Q3 2025, versus -$140.4 million for Q2 2025 and $44.7 million for Q1 2025.